Test on Gastroesophageal Reflux Disease (GERD) Management

Question 1: For individuals with mild and intermittent reflux-like symptoms who are treatment-naïve, the initial pharmacotherapy consists of a standard-dose proton pump inhibitor (PPI) for eight weeks.

A. Yes

B. No

Explanation: For individuals with mild and intermittent reflux-like symptoms who are treatment-naïve, the initial step in pharmacotherapy involves lifestyle modifications and as-needed antacids, sodium alginate, and/or low-dose H2RAs for four weeks, following a step-up approach. Standard-dose PPIs are considered in later steps if initial treatments are insufficient.

Question 2: The US Food and Drug Administration (FDA) approved vonoprazan for the treatment of nonerosive GERD in July 2024.

A. Yes

B. No

Explanation: The study materials state, "The US Food and Drug Administration (FDA) approved vonoprazan for the treatment of nonerosive GERD in July 2024; it has been used in Japan since 2015."

Question 3: Which of the following statements is true regarding the management of gastroesophageal reflux disease (GERD) in pregnant individuals?

A. Upper endoscopy is routinely recommended as an initial diagnostic step for pregnant patients with GERD symptoms.

B. Sucralfate, H2RAs, and PPIs (like omeprazole or lansoprazole) are generally considered safe for use during pregnancy.

C. Antacids containing sodium bicarbonate or magnesium trisilicate are safe for use in pregnant individuals.

D. The first step in managing GERD in pregnant patients involves immediately initiating proton pump inhibitors (PPIs).

Explanation: Initial management for GERD in pregnancy starts with lifestyle modifications and as-needed antacids, alginates, or sucralfate. If symptoms persist, H2RAs are added, and then PPIs if symptoms still do not resolve. Sucralfate, H2RAs, and PPIs (omeprazole, lansoprazole, pantoprazole) are considered safe in pregnancy. However, antacids containing sodium bicarbonate or magnesium trisilicate should be avoided. Upper endoscopy is only performed during pregnancy if a strong indication exists, such as significant gastrointestinal bleeding, and should be postponed until the second trimester if possible.

Question 4: For adult patients experiencing frequent (two or more moderate-to-severe episodes per week) or severe GERD symptoms that negatively impact their quality of life, which pharmacotherapy is initially suggested?

A. Antacids for immediate and brief symptom relief.

B. Standard-dose PPI therapy once daily for eight weeks, combined with lifestyle modifications.

C. Vonoprazan 20 mg once daily for eight weeks, as it is superior to PPIs in all cases.

D. Sodium alginate combined with an antacid for at least four weeks.

Explanation: For patients with frequent or severe GERD symptoms that impair quality of life, lifestyle modifications combined with standard-dose PPI therapy once daily for eight weeks are suggested to maximize rapid symptom relief. While vonoprazan is an alternative, it is typically used only when symptoms persist after an adequate trial of a PPI, and it is not considered superior to PPIs for symptom relief in patients without erosive esophagitis. Antacids and sodium alginate are generally for milder or intermittent symptoms, not severe or frequent ones.

Question 5: Peter J Kahrilas's financial relationship with Phathom, where he served on the Speaker's Bureau for Reflux disease, was not mitigated.

A. Yes

B. No

Explanation: The study materials explicitly state, "All of the relevant financial relationships listed have been mitigated," which includes Peter J Kahrilas's role on the Phathom Speaker's Bureau for Reflux disease.